Below are excerpts from the days we spent with teachers as they juggled the many duties that come with the job: delivering ...

David J. Adams serves as Indiana’s Secretary of Commerce and a member of Governor Mike Braun’s cabinet. Since his appointment in 2025, Adams has been instrumental in the transforming the state’s ...

The U.S. life sciences industry entered 2026 with surprising momentum, following threats of tariffs and disrupted trade, NIH funding cuts, and a sluggish IPO market. Accounting for more than ...

April 16 - OpenAI on Thursday introduced an artificial intelligence model touting increased biology knowledge and scientific research capabilities, as the startup deepens its push into the ‌life ...

El Salvador has published a new law that will allow authorities to penalise minors as young as 12 with life imprisonment for severe crimes, including homicide, terrorism or rape. On Tuesday, the ...

New Delhi: The National Council of Educational Research and Training (NCERT) on Friday released a new Class 9 science textbook, to be introduced from the 2026–27 academic session, integrating ...

The best-selling novelist explains why his new retelling of Homer’s epic offers the ideal antidote to the age of Trump Yann Martel’s writing studio, where he sits while we talk over Zoom, is a mere ...

Looking ahead: Expanded search strategies, improved computational power, and formal academic training are reshaping SETI into a mature scientific discipline. The timing is not accidental. SETI has ...

One of the world’s leading investment firms has broken its own record with the closing of its $6.3 billion Blackstone Life Sciences VI (BLXS VI) fund, which is 40% larger than its predecessor.

Blackstone Inc. closed its latest life-sciences fund with $6.3 billion of commitments, the firm’s biggest haul for backing clinical trials of medicines and technologies. The new vehicle, Blackstone ...

March 26 (Reuters) - Wave Life Sciences (WVE.O), opens new tab shares plunged 58% on Thursday after a higher dose of its experimental obesity ‌drug failed to show a clear improvement at reducing a ...

Wave Life Sciences (WVE) fell ~57% in the premarket on Thursday as Wall Street reacted to interim data from an early-stage trial for WVE-007, its RNA-based obesity medicine. Citing six-month follow-up ...